DoW Ovarian Cancer, Clinical Trial Award
About
Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e. g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
The DoW Ovarian Cancer Clinical Trial Award is designed for researchers, clinical institutions, and healthcare organizations committed to advancing ovarian cancer treatment and management through rigorous clinical trial implementation. This grant program supports the rapid development and execution of clinical trials that demonstrate significant potential to improve patient outcomes in ovarian cancer care. Applicants can propose trials evaluating innovative pharmacologic agents (drugs or biologics), medical devices, clinical guidance frameworks, and emerging technologies or approaches. The program accommodates a broad spectrum of trial designs—from small-scale proof-of-concept studies such as pilot projects, first-in-human trials, and phase 0 feasibility studies, through to large-scale efficacy trials in relevant patient populations. This flexibility makes the award particularly valuable for organizations looking to translate promising research into clinical practice efficiently. If your institution is developing or planning to implement a clinical trial with transformative potential for ovarian cancer patients, this award provides the support needed to move your project forward. The emphasis on rapid implementation means successful applicants can accelerate their timelines and demonstrate clinical impact. Entrepreneurs and clinical leaders in the oncology space should consider applying to advance their ovarian cancer research initiatives.
Funding Facts
● Applications openDeadline
October 1, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by trial scope and design
Deadline
2026-10-01
Grant Type
federal
Application Cycle
Annual (Next deadline: October 1, 2026)
Best For
Research institutions, clinical centers, and healthcare organizations conducting ovarian cancer clinical trials
Frequently Asked Questions
Who is eligible for DoW Ovarian Cancer, Clinical Trial Award?
Specific eligibility criteria are not detailed in the available information. Applicants should visit the official Department of Defense (DoD) Ovarian Cancer Research Program website or contact the program directly to confirm current eligibility requirements, which may include institutional affiliations, researcher qualifications, and trial design specifications.
How much funding does DoW Ovarian Cancer, Clinical Trial Award provide?
Specific funding amounts are not provided in the current program information. Award amounts may vary depending on trial scope, design complexity, and patient population size. For detailed information about funding ranges and budget requirements, please consult the official DoD OCRP announcement or contact the program administrators directly.
How do I apply for DoW Ovarian Cancer, Clinical Trial Award?
Application procedures, submission requirements, and deadlines are managed through the Department of Defense Ovarian Cancer Research Program. Visit the official DoD OCRP website or grants.gov for complete application instructions, required documentation, and current submission deadlines. The next application deadline is listed as October 1, 2026.
What can DoW Ovarian Cancer, Clinical Trial Award funding be used for?
Funding supports clinical trial implementation and design across multiple therapeutic approaches, including: evaluation of new pharmacologic agents (drugs and biologics), medical devices, clinical guidance protocols, and emerging technologies. Trials may range from proof-of-concept studies (pilot, first-in-human, phase 0) to demonstrate feasibility, through large-scale efficacy trials in relevant ovarian cancer patient populations.
Last updated: July 5, 2026